USPTO Examiner TAYLOR LIA ELAN - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18980920FCRN/HSA BINDING MOLECULES AND METHODS OF USEDecember 2024May 2025Allow501NoNo
18817152PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFAugust 2024May 2025Allow911NoNo
18773400VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCTJuly 2024June 2025Allow1120YesNo
18664201VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUSMay 2024January 2025Allow800YesNo
18627754Anti-SIRPa Antibodies and Methods of Use ThereofApril 2024November 2024Allow700NoNo
18601952ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USEMarch 2024December 2024Allow920NoNo
18442779CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODSFebruary 2024June 2025Allow1610NoNo
18440437SPECIFIC BINDING MOLECULESFebruary 2024March 2025Allow1310NoNo
18399934Novel Anti-Sema3a Antibodies And Uses ThereofDecember 2023August 2024Allow710NoNo
18389748ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USEDecember 2023February 2025Allow1401NoNo
18511744INTERFERON BETA ANTIBODIES AND USES THEREOFNovember 2023June 2025Allow1930NoNo
18506872PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFNovember 2023July 2024Allow811YesNo
18384223ANTIBODIES RECOGNIZING SORTILINOctober 2023April 2024Allow510NoNo
18486644ANTI-HUMAN MASP-2 ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFOctober 2023August 2024Allow1021NoNo
18240347BINDING PROTEINS TO THE HUMAN THROMBIN RECEPTOR, PAR4August 2023June 2025Allow2210NoNo
18356891Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)July 2023June 2024Allow1011NoNo
18198600METHOD OF INHIBITING EXACERBATIONS OF T CELL-MEDIATED ALLOGRAFT VASCULOPATHYMay 2023December 2024Abandon1911NoNo
18180225ANTI-CD3 ANTIBODIES AND USES THEREOFMarch 2023January 2025Allow2210NoNo
18173772ANTI-SPIKE GLYCOPROTEIN ANTIBODIES AND THE THERAPEUTIC USE THEREOFFebruary 2023March 2024Allow1200NoNo
18162985ANTI-HUMAN PD-L2 ANTIBODIESFebruary 2023May 2025Allow2711YesNo
17923503PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOFNovember 2022June 2025Allow3121NoNo
17938756POLYPEPTIDES THAT BIND COMPLEMENT COMPONENT C5 OR SERUM ALBUMIN AND FUSION PROTEINS THEREOFOctober 2022October 2024Allow2420NoNo
17934607IMMUNOGENIC CD1D BINDING PEPTIDESSeptember 2022March 2025Abandon3021NoNo
17933725ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USESeptember 2022December 2024Allow2721YesNo
17871211SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOFJuly 2022February 2024Allow1910NoNo
17870373SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOFJuly 2022January 2024Allow1830NoNo
17747798METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCERMay 2022August 2024Abandon2721NoNo
17746768SARS-COV-2 SPIKE PROTEIN ANTIBODIESMay 2022February 2024Abandon2110NoNo
17731226ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATESApril 2022November 2023Abandon1901NoNo
17707637Anti-SIRPa Antibodies and Methods of Use ThereofMarch 2022January 2024Allow2101NoNo
17677873ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USEFebruary 2022November 2023Allow2110NoNo
17677757BROADLY NEUTRALIZING ANTIBODIES AGAINST HIVFebruary 2022February 2025Allow3630NoNo
17675460MONOCLONAL ANTIBODY, MEASUREMENT REAGENT FOR CYTOKERATIN 18 FRAGMENT, REAGENT KIT, AND MEASUREMENT METHODFebruary 2022January 2024Allow2320NoNo
17674713AQUEOUS SOLUTION COMPOSITIONS FOR INCREASING STABILITY OF ENGINEERED DIMERIC PROTEINSFebruary 2022November 2024Abandon3341NoNo
17670270METHODS OF TREATMENT WITH ANTI-FACTOR XI/XIA ANTIBODIESFebruary 2022September 2024Abandon3111NoNo
17557440CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODSDecember 2021November 2023Allow2310NoNo
17551103ANTIBODY-DRUG CONJUGATE COMPRISING MODIFIED ANTIBODYDecember 2021June 2024Allow3021NoNo
17538334ANTIBODY FOR ENRICHMENT OF CELLSNovember 2021July 2025Allow4341NoNo
17516508GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOFNovember 2021September 2023Allow2210NoNo
17500537ANTI-GPIIB/IIIA ANTIBODIES OR USES THEREOFOctober 2021December 2023Abandon2601NoNo
17594255Anti-CD40 antibodies and uses thereofOctober 2021June 2025Allow4421NoNo
17481677ANTI-CHI3L1 ANTIBODIES FOR THE DETECTION AND/OR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE/ NONALCOHOLIC STEATONHEPATITIS AND SUBSEQUENT COMPLICATIONSSeptember 2021January 2024Allow2820NoNo
17411979METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIESAugust 2021January 2024Abandon2911NoNo
17404459ANTI-FACTOR IX PADUA ANTIBODIESAugust 2021January 2024Allow2920YesNo
17385908METHODS AND REAGENTS TO TREAT ALLERGYJuly 2021April 2024Abandon3220NoNo
17353402ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIESJune 2021January 2024Abandon3011NoNo
17334499Anti-Peripheral Lymph Node Addressin Antibodies and Uses ThereofMay 2021August 2024Allow3930NoNo
17329978Treatment and Prevention of Cardiovascular DiseaseMay 2021May 2024Abandon3611NoNo
17294147Antibodies Blocking DLL4-Mediated Notch SignallingMay 2021April 2025Allow4721YesNo
17293708SYNERGISTIC COMBINATIONS OF METHIONINE DEPLETION AGENTS AND IMMUNE CHECKPOINT MODULATORSMay 2021January 2025Abandon4401NoNo
17242170VARIANT NUCLEIC ACID LIBRARIES FOR CORONAVIRUSApril 2021February 2024Allow3311YesNo
17191764CORONAVIRUS NEUTRALIZING HUMANIZED ANTIBODIES AND USES THEREOFMarch 2021April 2024Allow3831YesNo
17254146ANTIDOTES TO FACTOR XA INHIBITORSDecember 2020October 2024Allow4621YesNo
17123656SELECTIVE ENRICHMENT OF ANTIBODIESDecember 2020March 2025Abandon5111NoNo
17103672METHODS FOR TREATING AND/OR PREVENTING IDIOPATHIC PNEUMONIA SYNDROME (IPS) AND/OR CAPILLARY LEAK SYNDROME (CLS) AND/OR ENGRAFTMENT SYNDROME (ES) AND/OR FLUID OVERLOAD (FO) ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTNovember 2020March 2024Abandon4011NoNo
17057867DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTSNovember 2020April 2025Allow5330YesNo
17092998INTERFERON BETA ANTIBODIES AND USES THEREOFNovember 2020August 2023Allow3310NoNo
17051137IN VIVO GENE THERAPY USING INTRAOSSEOUS DELIVERY OF A LENTIVIRALGENE CONSTRUCTOctober 2020September 2024Abandon4720YesNo
17046695C-TYPE NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIESOctober 2020January 2025Abandon5121NoYes
17065052Human Interleukin-2 and Anti-human Epithelial Cell Adhesion Molecule Single-Chain Antibody Fusion Protein and Application ThereofOctober 2020November 2024Abandon5021NoNo
17065368BIO-RESPONSIVE ADHESIVE ANTIBODY DELIVERY PLATFORM FOR IMMUNOTHERAPY AND PREPARATION METHOD THEREOFOctober 2020December 2024Allow5031YesNo
16982765METHODS AND COMPOSITIONS FOR ANTIBODY TO HIGH AFFINITY RECEPTOR FOR IGESeptember 2020April 2024Allow4321NoNo
17024094ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USESeptember 2020April 2023Allow3131NoNo
16980611ANTI-DENGUE VIRUS ANTIBODIES HAVING CROSS-REACTIVITY TO ZIKA VIRUS AND METHODS OF USESeptember 2020September 2023Allow3621NoNo
16968794CAR-T CELLS AND AUTOIMMUNE DISEASESAugust 2020June 2025Allow5841YesNo
16988076PAN-ANTIALLERGY VACCINEAugust 2020October 2023Allow3821YesNo
16963956Method for Delivering Drug to MuscleJuly 2020April 2024Abandon4531NoNo
16770840BISPECIFIC HIV-1-NEUTRALIZING ANTIBODIESJune 2020April 2024Allow4630NoNo
16890380BISPECIFIC MOLECULES COMPRISING AN HIV-1 ENVELOPE TARGETING ARMJune 2020August 2024Allow5021NoNo
16885797COMBINATION OF BROADLY NEUTRALIZING HIV ANTIBODIES AND VIRAL INDUCERSMay 2020October 2024Allow5351NoNo
16765752ANTIBODIES TO CITRULLINATED PROTEINSMay 2020August 2023Allow3941NoNo
16765274REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOFMay 2020October 2023Abandon4021NoNo
16758128ANTIBODY VARIANT AND ISOFORM WITH LOWERED BIOLOGICAL ACTIVITYApril 2020June 2025Allow6041YesNo
16841527Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific ImmunosuppressionApril 2020July 2023Allow3921YesNo
16650889SPECIFIC BINDING MOLECULESMarch 2020October 2023Allow4341YesNo
16650385NEW DUAL CHIMERIC ANTIGEN RECEPTOR-T CELL WHICH CAN BE REGULATED, CONSTRUCTION METHOD THEREFOR AND USE THEREOFMarch 2020January 2024Allow4631NoNo
16608257COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICSOctober 2019October 2023Abandon4731NoNo
16500251ANTIBODIES RECOGNIZING TAUOctober 2019December 2023Allow5031YesNo
16496089MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIIISeptember 2019November 2023Abandon5031NoNo
16484813ENGINEERED NATURAL KILLER (NK) CELLS AND COMPOSITIONS AND METHODS THEREOFAugust 2019October 2023Allow5131YesNo
16481108Procoagulant AntibodiesJuly 2019May 2024Allow5831YesNo
16478029NOVEL STABLE FORMULATION FOR FXIA ANTIBODIESJuly 2019May 2024Abandon5840NoYes
16435166COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIAJune 2019September 2024Allow6061YesYes
16428624CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) FOR THE TREATMENT OF CANCERMay 2019July 2024Abandon6041NoYes
16463748METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORSMay 2019September 2023Allow5231YesYes
16346896TREATMENT REGIMENSMay 2019December 2023Abandon5530NoYes
16400595METHODS FOR DETECTING AND REVERSING IMMUNE THERAPY RESISTANCEMay 2019March 2024Allow5851YesNo
16394223METHOD OF ACTIVATING DENDRITIC CELLSApril 2019December 2024Abandon6061NoNo
16333436ANTI-C-MET ANTIBODIES AND ANTIBODY DRUG CONJUGATES THEREOF FOR EFFICIENT TUMOR INHIBITIONMarch 2019November 2023Abandon5641NoNo
16320872ANTIBODIES TO ZIKA VIRUS AND METHODS OF USE THEREOFJanuary 2019July 2023Allow5431NoNo
16244090ANTIBODY PROTAC CONJUGATESJanuary 2019December 2024Abandon6051NoNo
16093495ANTIBODY-CONTAINING PREPARATIONOctober 2018April 2024Allow6060YesNo
16081829METHODS RELATED TO ENGINEERED Fc CONSTRUCTSAugust 2018May 2025Allow6051NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TAYLOR, LIA ELAN.

Strategic Value of Filing an Appeal

Total Appeal Filings
6
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
6
(100.0%)
Filing Benefit Percentile
0.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner TAYLOR, LIA ELAN - Prosecution Strategy Guide

Executive Summary

Examiner TAYLOR, LIA ELAN works in Art Unit 1641 and has examined 85 patent applications in our dataset. With an allowance rate of 67.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner TAYLOR, LIA ELAN's allowance rate of 67.1% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by TAYLOR, LIA ELAN receive 2.33 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TAYLOR, LIA ELAN is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.2% benefit to allowance rate for applications examined by TAYLOR, LIA ELAN. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.2% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 66.7% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 34.8% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.1% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.